HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.7%

Neg 0% Neu 88.7% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $10 price target.